TB R&D Weekly Update: Podcast interview with Dr. Gyanu Lamicchane

Gyanu Lamicchane
Gyanu Lamicchane

Listen to Gyanu Lamicchane Podcast

Summary: Microbial geneticist Dr. Gyanu Lamichhane of the Johns Hopkins Center for Tuberculosis Research is one of 49 recipients of the New Innovator Award, which is given to promising scientists in the early stages of their careers and is supported directly with $1.5 million in research funding over five years.

Dr. Lamichhane has discovered the key role of enzyme L,D-transpeptidase in forming chemical linkages inside the protective cell wall in Mycobacterium tuberculosis, the bacterium responsible for TB diseases. The same enzyme and chemical linkages help hold together the cell walls of other disease-causing bacteria, including salmonella, Enterococcus and Escherichia coli. In this interview, we discuss the award and the related research that lead to the award, as well as, Dr. Lamichhane’s motivation to work with TB.

Additional Coverage:

NIH Director’s Awards Go to Three Johns Hopkins Scientists for Work That Challenges the Status Quo and Speeds Translation of Research

NIH Director’s Awards go to three JHU scientists for work that challenges status quo, speeds translation of research

WGND Interview with Gyanu Lamicchane (May 13, 2010)

Additional TB R&D News:

Lack of Adherence to Isoniazid Chemoprophylaxis in Children in Contact with Adults with Tuberculosis in Southern Ethiopia

Paediatric tuberculosis: out of the dark

Lupin challenges tuberculosis drug price fixed by National Pharmaceutical Pricing Authority

ZAMSTAR study: community counseling cheap, effective way to combat TB

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...